But Alexander really liked the way Porus had fought in the battle and wanted to give the kingdom back to him. And Alexander got defeated for the first time and somehow he won during second time. Yes, they were facing elephants for the first time and the trumpeting elephants were making their horses mad. In the battle field, he and his men for the first time seeing something different and more powerful than his allies. I would like to add how I heard that this part of history ended. Alexander had no other way than to retreat back. He want everything inclusive of it i.e, he wants his kingdom and he should be "AS A KING" and Alexander asks what else he wants and he replies that Alexander asks Purushothama how he should treat him, he replies Later Alexander sent Meroes who was aĬlose friend of Purushothama and finally he agrees to stop the war and meetĪlexander. Purushothama to befriend Alexander but he strongly declined their offers and Purushothama declined his offer and also attackedĪmbi.
Greek historian, wrote that Alexander sent Ambi to ask Purushothama to stop the High on Purushothama's side but he has no intention of stopping the war. Stop the war because of heavy loss of men in the war. “The sheer number of (rare) diseases coupled with very few major pharma/biotechnology companies focusing on them offers a great opportunity for companies like (Aten).It very difficult to continue the war. “Rare diseases have a fast-track approval with orphan designation and lot of incentives from regulatory bodies such as the USA-FDA and European-EMA,” said Namala. It also secured the Rs 50-lakh Biotechnology Ignition Grant instituted by the government-funded Biotechnology Industry Research Assistance Council. Aten Porus this week raised $1.4 million (about Rs 9.3 crore) for its subsidiary Oraxion Therapeutics from an undisclosed US-based pharmaceutical trading company.Īten previously raised $1 million from Srinivasan Namala, CEO of Hyderabad-based Porus Labs, who is now also a partner in the company. The plan is for Aten to partner with pharma companies that have marketing, production and distribution muscle. What our drug could do is, the moment cholesterol is accumulated it is removed from the body,” said Kulkarni. “If you look at the various diseases we want to tackle and distil them down, the underlying factor for each of these diseases is excess accumulation of cholesterol and lipids. With the initial success, the duo wanted to test if the same thought process could be used to expand use of the drug for other cholesterol-related diseases or disorders. “Based on the strategy design of this drug and the encouraging results we have obtained up to now, I believe that it has the potential to represent a major breakthrough for the treatment of NPC disease and perhaps other lysosomal disorders,” said Fiorenza.
Importantly, it can potentially result in a 30-50% reduction in cost. Not only could we show that the lifespan of mice could be doubled with our drug, but also that brain damage could be stopped.” The pair say their formulation is better than existing options as it allows for fewer doses to be administered and in easier ways.
If you take NPC, there are only 10-15 professors globally who are experts,” said Papaiah, chief executive of Aten Porus. The earliest breakthrough came from tests conducted by Maria Teresa Fiorenza, associate professor of applied biology in the Faculty of Medicine and Psychology at Sapienza University in Rome. Kulkarni went about formulating the drugs and began reaching out to experts at foreign universities for testing Aten’s formulations on animals. Globally, according to Kulkarni, fewer than 2,500 people are estimated to be afflicted with this disorder.
0 kommentar(er)
